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Abstract A novel isoform of a major rye grass pollen allergen
Lol p 5 was isolated from a cDNA expression library. The new
isoform, Lol p 5C, shares 95% amino acid sequence identity with
Lol p 5A. Both isoforms demonstrated shared antigenic activity
but different allergenic activities. Recombinant Lol p 5C
demonstrated 100% IgE reactivity in 22 rye grass pollen
sensitive patients. In comparison, recombinant Lol p 5A showed
IgE reactivity in less than 64% of the patients. Therefore, Lol p
5C represents a novel and highly IgE-reactive isoform allergen of
rye grass pollen.
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1. Introduction
Grass pollen sensitisation is a well known cause of hayfever
and allergic asthma [1], a¡ecting 25^30% of the population in
developed countries [2]. In Australia, rye grass (Lolium pe-
renne) pollen is the major contributor to air£ora as it is ex-
tensively sown as an agriculturally viable livestock feed crop
and is capable of producing up to half a tonne of pollen per
hectare [3]. Major or dominant allergens of rye grass pollen
include Lol p 1 and Lol p 5, and 90% of individuals allergic to
rye grass pollen demonstrate IgE reactivity to both of these
allergens [4]. Immunocytological studies have shown that Lol
p 1 is located in the cytosol of rye grass pollen while Lol p 5 is
localised in starch granules [1,5]. Lol p 5’s unique localisation
in starch granules, and release of such granules into the at-
mosphere as allergenic micronic particles, have prompted us
to identify its role as a trigger of allergic asthma [6,7]. These
¢ndings were also con¢rmed for the timothy grass allergens,
Phl p 1 and Phl p 5 [8]. However, the biological function of
grass pollen allergens largely remains unknown with the ex-
ception of Cyn d 7, from Bermuda grass pollen, which we
have recently identi¢ed and immunologically characterised
as a calcium-binding allergen [9].
Di¡erent isoforms of each allergen are identi¢ed by a letter
designation following the group number (i.e. Lol p 5A, Lol p
5B etc.), according to the International Union of Immunolog-
ical Societies (IUIS) [10]. Indeed, it has been shown that when
crude rye grass pollen extract is separated by two-dimensional
(2D)-PAGE and replica immunoblots screened with Lol p 1-
and Lol p 5-speci¢c monoclonal antibodies, Lol p 1 contains
four isoforms while Lol p 5 contains eight [11]. Isoforms of a
protein are essentially the same proteins, often with the same
molecular mass (Mr) but with di¡erent isoelectric points (pI),
that exhibit slight physicochemical and immunological di¡er-
ences and share a signi¢cant sequence identity at both the
nucleic and amino acid level. Cloning of cDNAs encoding
Lol p 1 [12,13], and Lol p 5 [14,15], as well as those from
other grass pollen [16^18], has shown that each allergen con-
sists of a family of similar but distinguishable sequences.
These sequence di¡erences highlight the need to assess the
relative potency or clinical signi¢cance of all isoforms and
identify common and/or unique IgE binding epitopes [19].
Such characterisation studies are mandatory for the design
of standardised and e¡ective diagnostics and production of
hypoallergenic variants for immunotherapy.
In this paper, we report the cDNA cloning and immuno-
logical characterisation of a novel isoform of rye grass pollen
allergen Lol p 5, designated Lol p 5C according to IUIS [10],
demonstrating high frequency and intensity of IgE reactivity.
It is anticipated that such cloning studies will permit the pro-
duction of hypoallergenic mutants of Lol p 5C, in which B cell
epitopes are abrogated, allowing its use as a safer and more
e¡ective immunotherapy reagent, without the current risk of
IgE-mediated systemic reactions [20].
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2. Materials and methods
2.1. Human sera and murine monoclonal antibodies
Human sera were obtained, with oral and written consent, from
grass pollen allergic and non-allergic individuals attending the Allergy
Clinic at the Alfred Hospital. Allergic status was de¢ned by a history
of grass pollen allergy, positive skin prick test to rye grass pollen and
the presence of serum IgE speci¢c to rye grass pollen, as determined
by radioallergosorbent test (RAST). Lol p 5-speci¢c monoclonal anti-
body FMC A7 (12.33) was produced at the Flinders Medical Centre
(Adelaide, S.A., Australia) in 1983 [21] by immunisation of mice with
crude rye grass pollen extract and screening for monoclonal murine
antibodies (mAbs) which recognised human IgE binding proteins.
2.2. Construction and screening of cDNA library
Total RNA was extracted from rye grass pollen (L. perenne) using
the method of Chomczynski and Sacchi [22]. Polyadenylated RNA
was puri¢ed using an oligo(dT) a⁄nity column (Pharmacia, Sweden)
and a cDNA library constructed in the expression vector V ZAP II
(Stratagene, CA, USA) using a Time-Saver cDNA synthesis kit (Phar-
macia, Sweden) following manufacturer’s instructions. Screening of
the cDNA library was accomplished by taking plaque lifts and, fol-
lowing denaturation and neutralisation, probing with 32P random
primed (Bresatec, Australia) cDNA clone encoding Lol p 5A, follow-
ing established methods [23]. After washing and exposure of ¢lters to
X-ray ¢lm, positive clones were identi¢ed, excised from the master
plate and di¡erent dilutions of clones were re-plated and re-probed
to isolate individual and therefore, pure plaques.
2.3. Isolation and sequencing of cDNA clones
cDNA inserts from V ZAP II clones were sub-cloned into pBlue-
script SK vectors (Stratagene, CA, USA) by co-infecting Escherichia
coli SOLR cells with the V ZAP II phage and f1 helper phage, accord-
ing to the manufacturer’s instructions. DNA sequence was determined
by the dideoxy chain termination method [24] using a T7 DNA se-
quencing kit (Pharmacia-LKB, Uppsala, Sweden) according to the
manufacturer’s instructions and also con¢rmed by automated se-
quencing (Applied Biosystems, USA). Sequence analysis, including
amino acid (aa) deduction, was performed using the software program
DNA Strider (Commissariat a l’Energie Atomique, France). The nu-
cleotide (nt) and aa sequences of Lol p 5C were searched for compar-
ison with other sequences in the Australian National Genomic Infor-
mation Service (ANGIS) database which incorporates databases from
the following major sources: GenBank, EMBL and NBRF nucleic
acid libraries, NBRF PIR protein and Swiss-Prot libraries. The nt
and deduced aa sequences of the Lol p 5C cDNA have been submit-
ted to the EMBL/GenBank databases under the accession number
AJ243504.
2.4. Expression and puri¢cation of rLol p 5C
The cDNA inserts encoding Lol p 5C and Lol p 5A were ligated, in
frame, into the pProEx HT expression vector (Life Technologies,
USA) following the manufacturer’s instructions and transformed
into competent cells of E. coli strain DH5K (Life Technologies,
USA). In order to determine the optimal conditions for expression
of recombinant proteins (i.e. rLol p 5C and rLol p 5A), small scale
time-course induction of pProEx-Lol p 5A/C was performed as per
the manufacturer’s instructions. The 4 h post-induction time point
was chosen as the optimal induction time. Total bacterial proteins
were obtained B-PER bacterial protein extraction reagent (Pierce,
USA) following the manufacturer’s instructions. rLol p 5A/C aller-
gens were puri¢ed from the crude bacterial lysates by mAb A7-a⁄nity
chromatography (ImmunoPure protein G IgG Orientation kit; Pierce,
USA), following the manufacturer’s instructions.
2.5. SDS and 2D gel electrophoresis
Pollen of rye grass (L. perenne) was purchased from Greer Labo-
ratories (Lenoir, NC, USA) and total proteins extracted as described
previously [25]. Total pollen and bacterial proteins (30 Wg/lane), pu-
ri¢ed rLol p 5A/C proteins (5 Wg/lane) and pre-stained molecular
weight markers (Novex, CA, USA; 5 Wl/lane) were resolved on
12.5% ‘mini’ SDS-PAGE gels in a Xcell II Mini-Cell (Novex, CA,
USA), following the manufacturer’s instructions. The ¢rst dimension,
or isoelectric focussing (IEF), of crude rye grass pollen extract
(CRPE) was performed with immobilised pH gradient (IPG) strips
and electrophoresed on Multiphor (Pharmacia, Sweden), following
the manufacturer’s instructions. The second dimension (i.e. SDS-
PAGE) was performed using 4^15% gradient ‘mini-gels’ as described
above. Gels were either stained for total proteins with Coomassie
brilliant blue [25] or transferred onto nitrocellulose (NC) membrane
for immunological studies as described below.
2.6. Immunological analysis and inhibition studies
SDS-PAGE gels containing total grass pollen proteins, puri¢ed rLol
p 5A/C or IEF resolved CRPE were transferred onto NC using Xcell
II blotting apparatus (Novex, CA, USA), following the manufactur-
er’s instructions. Immuno-dot-blots involved the pipetting of CRPE
(1 Wg/Wl/dot) and a⁄nity-puri¢ed natural Lol p 5 and rLol p 5A/C
proteins (0.2 Wg/Wl/dot) onto NC membrane grids and allowing them
to air-dry. Following immobilisation of proteins onto NC membranes,
all blots were blocked in 10% w/v skim milk powder in PBS and
probed for either mAb FMC A7 (cell culture supernatant diluted
1:9, 5 ml/blot) or human IgE binding (dot-blot: individual sera di-
luted 1:4, 1 ml/blot; SDS-PAGE blot: serum pool of 10 grass pollen
allergic individuals diluted 1:4, 5 ml/blot) following established pro-
tocols [25]. Negative control blots were probed with a serum pool of
three non-allergic individuals while ‘no serum/mAb’ controls were
probed with the secondary and/or tertiary detection antibodies only.
Negative control blots failed to demonstrate any antibody binding.
Inhibition studies involved NC blots of total rye grass pollen pro-
teins, incubated in a 10 grass pollen allergic patient serum pool (di-
luted 1:4, 5 ml/blot) either in the absence (positive control) or pre-
incubated for 1 h at room temperature in the presence of potential
inhibitors of IgE binding [19,25]. Inhibitors included a⁄nity-puri¢ed
rLol p 5A and rLol p 5C (100 Wg/5 ml serum/blot). 2D blots used the
same serum pool (diluted 1:4, 5 ml/blot) and a⁄nity-puri¢ed rLol p
5A/C were used as the inhibitors (50 Wg/5 ml serum/blot). Similarly,
NC blots containing SDS-PAGE resolved CRPE and a⁄nity puri¢ed
rLol p 5A/C, were probed with mAb FMC A7 (cell culture super-
natant diluted 1:9, 2.5 ml/blot) and a⁄nity-puri¢ed rLol p 5A/C were
used as the inhibitors (50 Wg/2.5 ml/blot).
3. Results and discussion
3.1. Molecular cloning and characterisation of Lol p 5C
Seven positive clones were identi¢ed from the rye grass
pollen cDNA expression library. All positive clones were rec-
ognised by IgE antibodies from a pool of sera taken from
grass pollen allergic patients while no signal was detected
when plaques were screened with non-allergic human sera
and no serum antibody controls. The ability of these clones
to hybridise to Lol p 5A and bind to speci¢c IgE antibodies in
the sera of grass pollen sensitive individuals identi¢ed these as
encoding Lol p 5 allergens. Consequently, in order to deter-
mine whether any of these clones encoded novel allergen iso-
forms of Lol p 5, they were sub-cloned into the pBluescript
SK vector to permit DNA sequencing. Although sequentially
di¡erent to Lol p 5A, a number of the positive clones did not
encode full-length proteins. Also, some of the clones were
identical to Lol p 5A and were therefore omitted from further
study. However, one full-length clone, clone 4, demonstrated
some sequence di¡erences from Lol p 5A throughout the mol-
ecule and in particular in the 3P untranslated region (Fig. 1).
The nt sequence of cDNA clone 4 has an open reading frame
(ORF) of 906 base pairs (bp) starting with an ATG initiation
codon at position 32 and terminating with a TGA stop codon
at position 935 (Fig. 1). It also contains a complete 3P un-
translated region containing a poly (A) tail. The ORF enc-
odes a mature protein of 276 aa (V27.5 kDa) with a calcu-
lated pI of 6.5. In comparison, Lol p 5A cDNA encodes a
mature protein of 276 aa (V27.3 kDa) with a calculated pI of
6.7 while Lol p 5B encodes a 314 aa protein (V31.3 kDa)
with a pI of 7.1 [14,15]. Comparison of the deduced aa se-
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quence of clone 4 with that of Lol p 5A and Lol p 5B in-
dicates a high level of similarity (Fig. 2). Clone 4 shares 95%
sequence identity with Lol p 5A and 56% identity with Lol p
5B, while there is only 56.6% identity between Lol p 5A and
Lol p 5B (Table 1). Therefore, clone 4 encodes a novel Lol p 5
isoform that is more similar to Lol p 5A than Lol p 5B.
However, although clone 4 is highly similar to Lol p 5A, clone
4 also possesses 11 unique aa residues among which is an
Fig. 1. Nucleic and deduced aa sequences of Lol p 5C. Numbers on margins correspond to bp positions. Numbers above the nt sequence refer
to aa positions. Negative numbers refer to the signal peptide, which is cleaved o¡ from the mature protein. The 5P underlined sequence repre-
sents the adapter used during cDNA synthesis and the italic sequence refers to the multiple cloning site of the vector DNA sequence. Asterisk
corresponds to the TGA stop codon.
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additional cysteine residue (Fig. 2). Thus, it is assumed that
clone 4 would encode a protein that may adopt a totally
di¡erent secondary and/or tertiary structure (i.e. via a disul-
¢de bond) to that of Lol p 5A (and also Lol p 5B) and may
also have di¡erent allergenic activity. Consequently, clone 4
was named Lol p 5C, in accordance with IUIS nomenclature
[10], and its sequence submitted to the EMBL/GenBank Nu-
cleotide Sequence Databases under accession number
AJ243504.
3.2. Immunological characterisation of Lol p 5C
The cDNA encoding Lol p 5C was sub-cloned into the
pProEx HT bacterial expression vector to express rLol p 5C
(rLol p 5C) and to assess its immunological properties. Fig.
3A shows the time-course of induced and non-induced E. coli
cells containing the Lol p 5C cDNA-vector. There is no ex-
pression of Lol p 5C in non-induced cells (Fig. 3A, lanes 1, 3,
5, 7). However, 2 h after induction, accumulation of rLol p
5C is evident at V27 kDa (Fig. 3A, lane 4). Expression peaks
at 4 h (Fig. 3A, lane 6) and declines signi¢cantly by 8 h post-
induction (Fig. 3A, lane 8). Therefore, the optimal expression
for rLol p 5C was chosen to be 4 h post-induction.
In order to assess if rLol p 5C was immunologically reac-
tive, replica gels of the time-course were blotted onto NC and
probed with patient serum IgE or the Lol p 5-speci¢c mono-
clonal antibody, FMC A7 (Fig. 3B,C, respectively). Indeed,
rLol p 5C was IgE reactive and corresponded to the protein
band observed on the Coomassie-stained gel as rLol p 5C
(Fig. 3B). No IgE binding was detected with serum taken
Fig. 2. Comparison of the deduced aa sequence of Lol p 5C with other cloned and sequenced Lol p 5 isoforms. Numbers refer to aa residues.
Gaps represented by dashes (^) have been introduced to ensure maximum homology. Lol p 5A and Lol p 5B deduced aa sequences are from
reference [14] and have the accession numbers M59163 and L13083, respectively. Amino acid residues common to all isoforms are represented
by dots (W). Underlined aa residues of Lol p 5C sequence represent residues common to only Lol p 5A and Lol p 5C. Italic aa residues of Lol
p 5C sequence represent residues common to only Lol p 5B and Lol p 5C. Bold aa residues of Lol p 5C sequence indicate residues unique to
Lol p 5C.
Table 1
Percentage identity between the deduced aa sequences of Lol p 5C
and other Lol p 5 isoforms, as shown in Fig. 2
Lol p 5A Lol p 5B Lol p 5C
Lol p 5A 56.6% 95%
Lol p 5B 56.6% 56%
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from non-allergic individuals and no serum controls. Once
again, optimal IgE binding was observed for the 4 h time-
point (Fig. 3B, lane 8). Although Lol p 5A demonstrates
speci¢c binding to mAb FMC A7, Lol p 5B does not [14].
Therefore, it was of great interest to determine whether the
epitope responsible for mAb binding was conserved in Lol p
5C. Fig. 3C demonstrates intense mAb FMC A7 binding to
rLol p 5C; especially at the 4 h time-point (Fig. 3C, lane 6).
No secondary antibody binding was detected when mAb
FMC A7 was omitted from the immunoblotting procedure.
We have recently reported the IgE and mAb FMC A7 bind-
ing epitopes of Lol p 5A [19]. The monoclonal antibody rec-
ognised Lol p 5A (aa 49^60), an epitope which has a 92%
identity with Lol p 5C (aa 49^60) and only 67% identity
with Lol p 5B (i.e. Lol p 5C (aa 74^85) in Fig. 2) [19]. On
the other hand, a number of IgE binding epitopes were de-
tected in Lol p 5A, with two epitopes demonstrating high
a⁄nity to human IgE. One of these was, once again, Lol p
5A (aa 49^60) and the other was Lol p 5A (aa 265^276) (i.e.
Lol p 5C (aa 290^301) in Fig. 2) [19]. The latter epitope shows
92% identity with Lol p 5C, while only 67% identity exists
between Lol p 5A and Lol p 5B (Fig. 2). However, the aa
residues critical for IgE binding to this epitope have been
con¢ned to Lol p 5A (aa 272^275), an area demonstrating
100% identity with Lol p 5B and Lol p 5C (i.e. Lol p 5C
(aa 297^300) in Fig. 2).
3.3. Immunological similarity between Lol p 5A and Lol p 5C
proteins
Fig. 4 demonstrates CRPE resolved by SDS-PAGE (lane 1)
and NC blots probed for total IgE binding (lane 2) with
serum pool from grass pollen allergic patients, and the serum
pool pre-incubated with either rLol p 5A or rLol p 5C (lanes 3
and 4, respectively). Total IgE recognised all major allergens
of CRPE, including the usual 2 or 3 protein bands corre-
sponding to natural Lol p 5 (nLol p 5) around the 28^30
kDa region [19]. However, pre-incubation of the serum pool
with puri¢ed rLol p 5A, reduced IgE binding to a higher band
of nLol p 5 (Fig. 4, arrow a). On the other hand, pre-incuba-
tion of the serum pool with rLol p 5C reduced IgE binding to
the lower nLol p 5 protein band (Fig. 4, arrow b) and, more
interestingly, to a group of 2 or 3 allergens around the 50 kDa
region (Fig. 4, arrow c) which may represent dimer forms of
Lol p 5C (or related proteins). Our proposed explanation for
this observation in regard to the 50 kDa allergens comes from
our results with the same experiment conducted with CRPE
resolved by 2D-SDS-PAGE (Fig. 5). In the 2D gels, occurence
of the 50 kDa allergens was less obvious, perhaps due to
presence of urea in the sample bu¡er. Indeed, addition of
urea to the CRPE samples resolved by SDS-PAGE decreased
both the protein amount and IgE reactivity of proteins in this
Fig. 3. Bacterial expression and immunoblot analysis of rLol p 5C.
Time-course of bacterial protein expression of cells containing
cDNA encoding Lol p 5C and analysis on a gel stained with Coo-
massie (A), or transferred onto NC and probed with a serum pool
from grass pollen allergic individuals (B), or Lol p 5-speci¢c mAb
FMC A7 (C). Mr markers are in lane M. Samples were taken at 0
(lanes 1, 2), 2 h (lanes 3, 4), 4 h (lanes 5, 6) and 8 h intervals after
induction. Odd numbered lanes represent the uninduced culture and
even numbered lanes represent the induced culture. Arrows point to
the accumulation of rLol p 5C in the induced culture.
Fig. 4. Inhibition of IgE binding to CRPE by rLol p 5A and rLol
p 5C. Total proteins of CRPE were resolved by SDS-PAGE and ei-
ther stained with Coomassie (lane 1) or transferred onto NC for im-
munoblot analysis (lanes 2^4). Mr markers are in lane M. NC blots
were probed for IgE binding with a serum pool of grass pollen al-
lergic patients only (lane 2), or the same serum pool pre-incubated
either with a⁄nity-puri¢ed rLol p 5A (lane 3) or rLol p 5C (lane
4). Arrow (a) points to nLol p 5A (i.e. IgE binding of this protein
inhibited by rLol p 5A) and arrow (b) points to nLol p 5C (i.e. IgE
binding of this protein inhibited by rLol p 5C). Arrow (c) points to
a potential dimer of nLol p 5C or related proteins (i.e. IgE binding
of these proteins inhibited by rLol p 5C).
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region (data not shown), suggesting that Lol p 5C may occur
as a dimer in the natural extract.
In relation to 2D-PAGE resolved nLol p 5 at the 30 kDa
region, inhibition of IgE binding was very slight with rLol p
5A (Fig. 5C), due to low level of IgE reactivity of rLol p 5A.
However, rLol p 5C reduced IgE binding to several protein
spots occupying the relevant regions in terms of both Mr and
pI (Fig. 5D, arrows). No IgE binding was detected with sera
taken from non-allergic individuals. Therefore, it appears that
rLol p 5A and rLol p 5C may have di¡erent IgE binding
epitopes. In another experiment, looking at the antigenic sim-
ilarity between rLol p 5A and rLol p 5C, both allergen iso-
forms inhibited mAb FMC A7 binding to Lol p 5A and Lol p
5C as well as to nLol p 5 (Fig. 6), suggesting that both pro-
teins possess the same mAb FMC A7 binding epitope(s).
3.4. Biological and clinical signi¢cance of Lol p 5C
Unfortunately, cloning and sequencing of Lol p 5C did not
provide any new information regarding the biological function
or role of this allergen group in rye grass pollen. Unlike aller-
gens from other sources (e.g. house dust mites etc.), determi-
nation of biological function of pollen allergens with data-
base sequence search/comparisons has been largely unsuccess-
ful. However, we have recently reported, for the ¢rst time for
a grass pollen allergen, the cloning and immunological char-
acterisation of a novel calcium-binding Bermuda grass pollen
allergen, designated Cyn d 7 [9]. It is anticipated that the
speci¢c expression of grass allergens in the pollen grain indi-
cates their possible involvement with pollen germination and
pollen tube growth.
In order to obtain a more complete picture of rLol p 5C’s
IgE reactivity, and therefore its clinical signi¢cance in relation
to rLol p 5A, we obtained sera from 22 patients allergic to rye
Fig. 5. Inhibition of IgE binding to CRPE resolved by 2D-PAGE. Gels were either stained with Coomassie (A) or transferred onto NC for im-
munoblot analysis (B^D). NC blots were probed for IgE binding with a serum pool of grass pollen allergic patients only (B), or the same se-
rum pool pre-incubated either with a⁄nity-puri¢ed rLol p 5A (C) or rLol p 5C (D). Arrows point to nLol p 5C, or related, proteins to which
IgE binding was inhibited by rLol p 5C.
Fig. 6. Inhibition of mAb FMC A7 binding to CRPE and a⁄nity-
puri¢ed rLol p 5A and rLol p 5C. SDS-PAGE resolved CRPE
(lane 1) and a⁄nity-puri¢ed rLol p 5A (lane 2) and rLol p 5C (lane
3) either stained with Coomassie (A) or transferred onto NC for im-
munoblot analysis (B-D). NC blots were probed for mAb binding
only (B), or pre-incubated either with a⁄nity-puri¢ed rLol p 5A (C)
or rLol p 5C (D) then probed for mAb binding.
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grass pollen, possessing speci¢c IgE to nLol p 5, to probe dot-
blots of a⁄nity-puri¢ed rLol p 5A, rLol p 5C, nLol p 5 and
CRPE (Table 2). All of the patient sera showed IgE reactivity
to CRPE, and 68.2% were categorised as demonstrating
strong IgE binding. 72.7% of the patient sera showed strong
IgE binding to nLol p 5 and rLol p 5C. In contrast, only 9.1%
of the patient sera showed strong IgE binding to rLol p 5A
and 36.4% gave no IgE binding to rLol p 5A (Table 2). There-
fore, Lol p 5C appears to be a more clinically signi¢cant
allergen isoform of Lol p 5.
Recently, site-directed mutagenesis has been successful in
the reduction of IgE-reactivity of a major house dust mite
allergen Der p 2 [26] and a major birch pollen allergen, Bet
v 1 [27]. With the latter, analysis of the deduced aa sequences
of the di¡erent isoforms of Bet v 1 allergen, each with a
di¡erent IgE-reactivity, identi¢ed six critical aa residues [27].
Single aa substitutions at the six key aa residues of Bet v 1
resulted in a Bet v 1 mutant with extremely low reactivity to
serum IgE from birch pollen allergic patients [27]. However,
proliferation assays of allergen speci¢c T-cell clones demon-
strated that T-cell recognition was maintained. Therefore,
such studies highlight the importance of cloning and immuno-
logical characterisation of allergen isoforms in understanding
the molecular basis of IgE reactivity of allergens and, there-
fore, provide information in the design of novel hypoallergen-
ic mutants for the treatment of grass pollen induced allergies
[20].
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Table 2
Frequency and strength of IgE binding, from sera of 22 allergic and
three non-allergic individuals, to dot blots of CRPE (1 mg/dot) and
a⁄nity-puri¢ed natural (n; 0.2 mg/dot) and recombinant (r; 0. mg/
dot) Lol p 5 isoforms
Allergen Frequency of IgE binding (%)
Sera from allergic individuals
(n = 22)
Sera from
non-allergic
individuals
(n = 3)
Strong Moderate Weak None
CRPE 68.2 27.3 4.5 0 0
nLol p 5 72.7 22.7 4.6 0 0
rLol p 5A 9.1 31.8 22.7 36.4 0
rLol p 5C 72.7 22.7 4.6 0 0
Strength of IgE binding was assessed visually when compared to the
control background.
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